MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

About this update from Mangoceuticals, Inc.

Month over Month Growth of 336% and 54% Reduction in Customer Acquisition Cost (CAC) DALLAS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company” or “MangoRx”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that MangoRx has experienced initial success for its newly launched all-inclusive injectable Testosterone Replacement Therapy (TRT) treatment program priced at $99 per month. The new TRT offer includes all doctor visits and medical consultations, lab work and analysis, and the medication to the extent prescribed. More information about MangoRx’s $99 per month offer can be found here at https://trt.mangorx.com/products/trt. Month over month sales of MangoRx’s injectable TRT treatment program have increased 336% since launching in mid-December while at the same time reducing customer acquisition costs by 54%. We believe that this strong momentum reflects growing demand for convenient, effective TRT options and MangoRx’s focused efforts to optimize marketing efficiency and patient access through its proprietary telehealth platform. We expect TRT to be the primary growth driver for the Company going forward, as MangoRx continues to prioritize and invest in advancing its TRT offerings, including both injectable and oral formulations such as PRIME by MangoRx, powered by Kyzatrex®, to attempt to capture greater market share in this high-demand segment. “We are encouraged by this initial customer demand and sales acceleration in our injectable TRT product, which we believe demonstrates the value of our innovative approach to men’s hormone health and underscores TRT as our key strategic focus,” commented Jacob Cohen, Founder and CEO of Mangoceuticals Inc. “By combining effective TRT solutions with streamlined telehealth delivery and targeted cost efficiencies, we are seeking to become better positioned to support more men seeking reliable, discreet care. At the same time, we are committed to building a more comprehensive platform that delivers a wider range of wellness solutions, which we expect to strengthen our operational and financial foundation and position us for sustained growth.” According to The Business Research Company’s Testosterone Replacement Therapy Global Market Re...

View stock analysis, news, and events for Mangoceuticals, Inc.